Semaglutide injection has been approved for use in adults with type 2 diabetes for blood sugar control.

On January 30th, Hangzhou Xianweida Biotechnology Co., Ltd. announced that Xianyida has been approved by the National Medical Products Administration for blood sugar control in adult type 2 diabetes patients, making it the world's first approved and marketed cAMP-biased GLP-1 receptor agonist.